Effect of measles mumps rubella vaccine in treatment of common warts

Dhope, Anuja A; Madke, Bhushan; Singh, Adarshlata

doi:10.4103/ijdd.ijdd_1_17

Cited by 14 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When comparing the efficacy of the MMR vaccine in the treatment of common warts, our study reported 67.7% complete response which was higher than that reported by Na et al 18 (47.6%) and Dhope et al 19 (65%). Meanwhile, our results were lower than those reported by Abdelmaguid et al 20 (70%), Nofal and Nofal 21 (81.4%), and Chauhan et al 22 (82.4%).…”

Section: Discussioncontrasting

confidence: 70%

Intralesional Measles, Mumps, and Rubella Vaccine Versus IntralesionalCandidaAntigen in the Treatment of Common and Plantar Warts

et al. 2021

View full text Add to dashboard Cite

Background Intralesional immunotherapy has been effectively used in the treatment of warts; however, comparative studies between different antigens are limited. Objective To evaluate the efficacy and safety of intralesional measles, mumps, and rubella (MMR) vaccine compared with intralesional Candida antigen for the treatment of multiple common and plantar warts. Methods Sixty-eight adult patients with multiple common and plantar warts were randomly assigned into two groups, each containing 34 patients. The first group received intralesional MMR vaccine, while the second group received intralesional Candida antigen. Each treatment was injected into the largest wart at 2-week intervals until complete clearance or for a maximum of 5 sessions. Results The overall therapeutic response was higher in the Candida antigen group (73.5%) compared with the MMR group (67.7%); however, the difference was not statistically significant. Complete clearance of common warts was higher in the Candida antigen group, while that of plantar warts was higher in the MMR group. Adverse effects were transient and well tolerated in both groups. No recurrence was detected during the 6-month follow-up period. Conclusion Intralesional MMR and intralesional Candida antigen showed comparable efficacy and safety in the treatment of common and plantar warts.

show abstract

Section: Discussioncontrasting

confidence: 70%

Intralesional Measles, Mumps, and Rubella Vaccine Versus IntralesionalCandidaAntigen in the Treatment of Common and Plantar Warts

et al. 2021

View full text Add to dashboard Cite

show abstract

“…14 In a study by Dhope et al, erythema, swelling and flu like symptoms were seen after MMR injection in 25%, 20% and 10% respectively. 15 In Kenawi et al study with BCG antigen, flu like symptoms were noted in all patients with lesional ulceration in 26.7% and necrosis in 16.7%. 16 A study by Munnagi et al also showed that intralesional MMR is safer, better and effective treatment modality of multiple warts compared to BCG.…”

Section: Discussionmentioning

confidence: 88%

Therapeutic evaluation of intralesional measles, mumps and rubella vaccine in palmoplantar warts

Geetha

2019

Int J Res Dermatol

View full text Add to dashboard Cite

Background: Warts are common viral infections of the skin caused by human papilloma virus. Most of the treatment modalities for common warts remain unsatisfactory. Immunotherapy has become one of the important therapeutic modality. This study was conducted to evaluate the efficacy of intralesional measles, mumps and rubella (MMR) vaccine immunotherapy in palmoplantar warts.Methods: 60 patients of various age groups and both sexes who have single or multiple palmoplantar warts not on any other concurrent systemic or topical therapy were randomly included for the study. Patients with other types of warts, signs of other infection, pregnancy, lactation and immunosuppression were excluded from the study. MMR Vaccine was injected intralesionally at 2 week intervals until complete clearance or for a maximum of 3 treatments. The outcome in terms of treatment relapse, recurrences and adverse effects were evaluated.Results: Only 54 patients completed the study and 41 (75.9%) of them showed complete response and 13 (24%) of them showed partial or no response.Conclusions: Intralesional MMR vaccine therapy appears to be a safe and effective treatment option with no significant adverse effects and low recurrence.

show abstract

“…21 Another retrospective case control study in 2017 by Dhope et al where 40 common wart cases were divided randomly into 2 groups had MMR vaccine group reporting complete response of 65% in comparison to normal saline control group reporting 5%. 22 On the other hand in the same year, a clinical trial of 50 patients with verrucae in two groups, one had MMR group with oral zinc and the other had normal saline. In the first group complete disappearance was seen in 80% cases, 8% noted relative clearing and nil response in 12% cases.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of measles, mumps and rubella vaccine as immunotherapeutic agent for cutaneous viral warts

2020

View full text Add to dashboard Cite

Immunotherapy for management of cutaneous wart with measles, mumps and rubella vaccine (MMR) is a promising new modality of management. Evaluation of the same has been done by various studies over the years reporting its effectiveness. A literature search was done using PubMed and google scholar. This short narrative review documents the response rates in various clinical studies done till 2019 which have reported the efficacy of MMR vaccine as an immunotherapeutic agent which ranged from 26-84% graded as complete response which is complete clearance of the treated warts. These studies were performed for evaluating MMR vaccine as single agent or done in comparison with other therapeutic agents. The broad range of responses points to a need of doing further clinical studies which will substantiate the effectiveness of MMR vaccine in the treatment of cutaneous warts.

show abstract

Effect of measles mumps rubella vaccine in treatment of common warts

Cited by 14 publications

References 0 publications

Intralesional Measles, Mumps, and Rubella Vaccine Versus IntralesionalCandidaAntigen in the Treatment of Common and Plantar Warts

Intralesional Measles, Mumps, and Rubella Vaccine Versus IntralesionalCandidaAntigen in the Treatment of Common and Plantar Warts

Therapeutic evaluation of intralesional measles, mumps and rubella vaccine in palmoplantar warts

Effectiveness of measles, mumps and rubella vaccine as immunotherapeutic agent for cutaneous viral warts

Contact Info

Product

Resources

About